Eli Lilly gains after lifting annual revenue view

Eli Lilly and

Yesterday 13:51

Updates
** Eli Lilly LLY.N shares rise 9% to $1,404.50 
** The drugmaker lifts FY revenue forecast to $91 bln to $92 bln from prior $85 bln to $87 bln 
** Posts Q3 EPS of $7.48 — above estimates of $6.26
** Reports Q3 sales for diabetes drug Mounjaro at $10.72 bln, obesity drug Zepbound at $5.35 bln 
** Trims FY EPS view to $35 to $36 from prior $35.50 to $36.50 to factor in research charges from recent acquisitions
** Analysts on avg were expecting 2026 rev of $88.87 bln, EPS of $33.88 - data compiled by LSEG 
** Up to last close, stock up ~20% YTD

(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))